Latest Japan Approvals Include Entyvio, Imfinzi, World-First Indication

Takeda’s global blockbuster GI drug Entyvio has been approved in Japan, although its local sales prospects appear limited, while two novel cancer drugs from AstraZeneca and a world-first indication have also been cleared by the health ministry.

Japanese flag
NEW JAPAN APPROVALS INCLUDE ENTYVIO, IMFINZI • Source: Shutterstock

Takeda Pharmaceutical Co. Ltd.’s blockbuster gastrointestinal drug Entyvio (vedolizumab) has been approved in Japan, as a treatment and maintenance therapy for moderately to severely active ulcerative colitis (UC) in patients with an inadequate response to conventional (TNF-alpha antagonist) treatment.

The product was given formal clearance by the country's Ministry of Health, Labour and Welfare following an earlier positive review...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Japan

More from Asia